Abstract
FAM64A, a marker of cell proliferation, has been investigated as a potential biomarker in several cancers. In the present study, we examined the value of FAM64A expression in the diagnosis and prognosis of pancreatic cancer through bioinformatics analysis of data obtained from The Cancer Genome Atlas (TCGA) database. The diagnostic value of FAM64A expression in pancreatic cancer tissue was deteremined through receiver operating characteristic (ROC) curve analysis, and based on the obtained cut-off value, patients were divided into two groups (high FAM64A expression and low FAM64A expression). Chi-square and Fisher exact tests were applied to identify associations between FAM64A expression and clinical features. Moreover, the effect of FAM64A expression in the survival of pancreatic cancer patients was observed by Kaplan-Meier and Cox analyses. Gene set enrichment analysis (GSEA) was performed using the TCGA dataset. Our results showed that high FAM64A expression in pancreatic cancer was associated with survival status, overall survival (OS), and recurrence. The area under the ROC curve was 0.736, which indicated modest diagnostic value. Patients with higher FAM64A expression had significantly shorter OS and recurrence-free survival (RFS) times. Multivariate survival analysis demonstrated that high FAM64A expression was an independent risk factor for OS and RFS. GSEA identified mitotic spindles, myc targets, MTORC1 signaling, G2M checkpoint, E2F targets, DNA repair, glycolysis and unfolded protein response as differentially enriched with the high FAM64A expression phenotype. In conclusion, high FAM64A mRNA expression is an independent risk factor for poor prognosis in pancreatic cancer.
Highlights
Pancreatic cancer is associated with a high mortality rate worldwide
FAM64A expression in pancreatic cancer and normal tissues was compared (Fig 1), and the results indicated that FAM64A expression was elevated in pancreatic cancer (P
Univariate and multivariate Cox analyses indicated the FAM64A mRNA expression may be a useful biomarker for pancreatic cancer prognosis, and receiver operating characteristic (ROC) analysis confirmed the diagnostic value of FAM64A expression in pancreatic cancer
Summary
The global incidence is relatively low (about 8/100000 persons per year) [1], the 5-year survival rate is less than 5%. Aberrant FAM64A mRNA expression: From dignosis to prognosis methods for early and accurate diagnosis of pancreatic cancer would help to improve outcomes for these patients. The diagnosis of pancreatic cancer is mainly based on imaging analyses, including computed tomography (CT) and magnetic resonance imaging (MRI). Even these imaging modalities are ineffective in some cases of pancreatic cancer [2]. The identification of a reliable biomarker for pancreatic cancer diagnosis and prognosis has clinical significance
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
